When pollen's buzzing around... : Rynacrom : disodium cromoglycate for hay fever.

Contributors

Fisons Limited

Publication/Creation

[approximately 1971]

Persistent URL


https://wellcomecollection.org/works/fqhvsxeb

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection 183 Euston Road London NW1 2BE UK T +44 (0)20 7611 8722 E library@wellcomecollection.org https://wellcomecollection.org





In the form of Intal, disodium cromo-glycate is already proven as a valuable anti-allergic therapy.^{1,5} The introduction of Rynacrom now makes disodium cromo-glycate available for the control of symptoms of hay fever. Administration is by a specially-designed nasal insufflator that is recharged with a Rynacrom capsule at each application. Clinical trial results show that Rynacrom significantly reduces rhinorrhoea and nasal obstruction in hay fever and that the treat-ment is easy and well accepted by patients.¹ A characteristic feature of DSCG therapy is for this reason many of the problems of conventional hay fever therapy do not arise with Rynacrom.


At the first sneeze of summer

Rynacrom is supplied as capsules contain-ing disodium cromoglycate 10 mg together with an inert carrier (Lactose BP 10 mg), for use in a specially-designed Rynacrom in-sufflator.

References: 1. Altounyan REC, and Howell JBL, Treatment of Asthma with Disodium Cromoglycate (FPL 670, 'Intal'). Respiration, 1969, 26, 131 (Suppl). 2. Kennedy MC S, Disodium Cromo-glycate in the Control of Asthma. A Double-Blind Trial. Brit J Dis Chest, 1969, 63, 96. 3. Backman A, Holopainen E, and Salo OP, Effect of Disodium Cromoglycate on Seasonal Allergic Rhinitis. Lancet, 1971, i. 55.



BEES OF THE BRITISH ISLES



shally emerge in early April ow ground. B terrestris has a st reach the nectar in red-cl ole in the corolla tubbe and flower does not become po terrestris is something of an terris is something or an-koo-bee Pathyrss vestalis so-bees can be distinguish of Bonhos by the fact tha uilar structures on their nitic and do not build th my young. They are often i killed before they can d

and killen over m Carder-bee (Boobss agror amon Carder-bee is variable by tawny, it lacks the contrast cies. Queens are observed for the set always enclosed in a w

ek Leafcies builds nests in h of hose pipe. The Le-eaf. The mutilation one grower. The Leaf-vers and honeyhere

Queen Honeybee (App millif(a)) The Hoorybee is domestic arisinal and has for harself in nature, hithough sometimes to queen and up to 60,000 workers and 2,000 confers themfolder colonies nervel worked does not foreign or build. She only produce does not foreign or build. She unly produce whole life. Both bumblebees and honeybee worked in the Roth bumblebees and honeybee professioned ages also of a

of Red-tailed Bumblebee (flow lebees usually establish nests can souse nests are a frourite site. oneypots and pollenpots, rst brood cell, indented where qu



RYNACROM

RYNACROM [®] for hay fever

Description: Rynacrom is a presentation for insufflation of disodium cromoglycate, 10 mg in powder form, together with an inert carrier (Lactose BP 10 mg).

Disodium cromoglycate has no anti-inflammatory or decongestant activity. Its principle action is to inhibit the release of inflammatory agents (such as histamine, bradykinin) from sensitised cells in the nose. This property offers a new approach to the management of seasonal allergic rhinitis prophylactic rather than symptomatic therapy.

Indication: Seasonal allergic rhinitis.

Administration: Rynacrom is presented in a single dose hard gelatin capsule for use in a specially developed nasal insufflator.

Dosage: 2 capsules 4 times daily.

Since disodium cromoglycate therapy is prophylactic, it is important that the patient be instructed to maintain regular dosage, as distinct from insufflating the drug intermittently to relieve symptoms.

Concomitant therapy: Concomitant antihistamine therapy can often be reduced or discontinued when the allergic rhinitis has been brought under control.

Withdrawal of Rynacrom therapy: As the action of disodium cromoglycate is prophylactic rather than curative, continuity of therapy is important in patients who have gained benefit. It should be borne in mind that symptoms of allergic rhinitis may recur when Rynacrom is discontinued. **Contra-indications:** There are no specific contra-indications. As with all new drugs, it is advisable, where possible, to avoid use during pregnancy, especially in the first trimester.

Side effects: No serious side effects attributable to disodium cromoglycate have so far been reported. Occasionally, slight irritation of the nose may occur on insufflation of the powder.

Pack and Price: Rynacrom is presented as capsules, supplied in packs of 100*. Basic NHS. cost £3 15.

*Instructions are supplied with each pack.



Further information is available from: The Technical Services Department, FISONS LIMITED — PHAR MACEUTICAL DIVISION Loughborough, Leicestershire, England.

Registered Trade Mark

RYN 4